IMCR Insider Trading

Insider Ownership Percentage: 9.10%
Insider Buying (Last 12 Months): $23,994,085.36
Insider Selling (Last 12 Months): $0.00

Immunocore Insider Trading History Chart

This chart shows the insider buying and selling history at Immunocore by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$24Mbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

Immunocore Share Price & Price History

Current Price: $29.64
Price Change: Price Decrease of -0.17 (-0.57%)
As of 03/24/2025 05:00 PM ET

This chart shows the closing price history over time for IMCR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$29.64Closing price on 03/24/25:

Immunocore Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Immunocore (NASDAQ:IMCR)

84.50% of Immunocore stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IMCR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$99Mbought$59MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
Immunocore logo
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Read More on Immunocore

Today's Range

Now: $29.64
Low: $29.09
High: $30.01

50 Day Range

MA: $29.98
Low: $28.20
High: $33.00

52 Week Range

Now: $29.64
Low: $27.19
High: $66.00

Volume

377,414 shs

Average Volume

436,082 shs

Market Capitalization

$1.48 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Who are the company insiders with the largest holdings of Immunocore?

Immunocore's top insider shareholders include:
  1. Bros Advisors Lp Baker (Director)
  2. Leger Tina Amber St (Insider)
Learn More about top insider investors at Immunocore.

Who are the major institutional investors of Immunocore?

Immunocore's top institutional investors include:
  1. T. Rowe Price Investment Management Inc. — 13.39%
  2. Wellington Management Group LLP — 13.23%
  3. FMR LLC — 9.63%
  4. Primecap Management Co. CA — 5.33%
  5. Price T Rowe Associates Inc. MD — 4.37%
  6. Tang Capital Management LLC — 3.11%
Learn More about top institutional investors of Immunocore stock.

Which major investors are selling Immunocore stock?

During the last quarter, IMCR stock was sold by these institutional investors:
  1. Wellington Management Group LLP
  2. Polar Capital Holdings Plc
  3. Two Sigma Investments LP
  4. Renaissance Technologies LLC
  5. Marshall Wace LLP
  6. Two Sigma Advisers LP
  7. Millennium Management LLC
  8. Bank of America Corp DE

Which major investors are buying Immunocore stock?

In the previous quarter, IMCR stock was acquired by institutional investors including:
  1. Groupama Asset Managment
  2. Deep Track Capital LP
  3. Tang Capital Management LLC
  4. Point72 Asset Management L.P.
  5. T. Rowe Price Investment Management Inc.
  6. Primecap Management Co. CA
  7. BNP Paribas Financial Markets
  8. Jefferies Financial Group Inc.